Compare RELL & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RELL | RCEL |
|---|---|---|
| Founded | 1947 | N/A |
| Country | United States | United States |
| Employees | N/A | 226 |
| Industry | Electronic Components | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 160.3M | 171.5M |
| IPO Year | 2004 | N/A |
| Metric | RELL | RCEL |
|---|---|---|
| Price | $14.71 | $4.30 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.88 |
| AVG Volume (30 Days) | 84.7K | ★ 189.0K |
| Earning Date | 04-08-2026 | 05-14-2026 |
| Dividend Yield | ★ 1.75% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | ★ $208,909,000.00 | N/A |
| Revenue This Year | $6.32 | $17.17 |
| Revenue Next Year | $7.91 | $49.82 |
| P/E Ratio | $230.96 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.66 | $3.22 |
| 52 Week High | $15.61 | $7.12 |
| Indicator | RELL | RCEL |
|---|---|---|
| Relative Strength Index (RSI) | 60.38 | 49.70 |
| Support Level | $10.53 | $4.37 |
| Resistance Level | $15.04 | $4.57 |
| Average True Range (ATR) | 0.66 | 0.26 |
| MACD | 0.02 | -0.03 |
| Stochastic Oscillator | 64.36 | 55.80 |
Richardson Electronics Ltd provides engineered solutions, power grid, and microwave tubes and related consumables, power conversion, RF and microwave components, high-value flat panel detector solutions, replacement parts, tubes, and service training for diagnostic imaging equipment and customized display solutions. The company's segment includes Power and Microwave Technologies, Green Energy Solutions, Canvys, and Healthcare. The company generates the majority of its revenue from the Power and Microwave Technologies segment, which includes the power grid and microwave tube business and RF, Wireless and Power technologies.
Avita is largely a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently used in most of the 140 US burn centers. Despite having product approval in Australia, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region, although international sales, particularly in Japan, are growing. Avita is domiciled, and has its primary listing, in the US.